These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12189723)

  • 1. Preformulation studies as an essential guide to formulation development and manufacture of protein pharmaceuticals.
    Volkin DB; Sanyal G; Burke CJ; Middaugh CR
    Pharm Biotechnol; 2002; 14():1-46. PubMed ID: 12189723
    [No Abstract]   [Full Text] [Related]  

  • 2. Aseptic processing of protein pharmaceuticals.
    Townsend M
    Pharm Biotechnol; 2002; 14():129-89. PubMed ID: 12189724
    [No Abstract]   [Full Text] [Related]  

  • 3. The stability factor: importance in formulation development.
    Krishnamurthy R; Manning MC
    Curr Pharm Biotechnol; 2002 Dec; 3(4):361-71. PubMed ID: 12463418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Getting to the core of protein pharmaceuticals--Comprehensive structure analysis by mass spectrometry.
    Leurs U; Mistarz UH; Rand KD
    Eur J Pharm Biopharm; 2015 Jun; 93():95-109. PubMed ID: 25791210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Screening Tools Used in High-Concentration Protein Formulation Development.
    Hofmann M; Gieseler H
    J Pharm Sci; 2018 Mar; 107(3):772-777. PubMed ID: 29102552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein formulation and fill-finish operations.
    Patro SY; Freund E; Chang BS
    Biotechnol Annu Rev; 2002; 8():55-84. PubMed ID: 12436915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of drug product development.
    Narayan P
    Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody structure, instability, and formulation.
    Wang W; Singh S; Zeng DL; King K; Nema S
    J Pharm Sci; 2007 Jan; 96(1):1-26. PubMed ID: 16998873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation development and stability testing of oral morphine solution utilizing preformulation approach.
    Preechagoon D; Sumyai V; Tontisirin K; Aumpon S; Pongjanyakul T
    J Pharm Pharm Sci; 2005 Aug; 8(2):362-9. PubMed ID: 16124948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High throughput formulation: strategies for rapid development of stable protein products.
    Nayar R; Manning MC
    Pharm Biotechnol; 2002; 13():177-98. PubMed ID: 11987752
    [No Abstract]   [Full Text] [Related]  

  • 12. Thermo-Optical Protein Characterization for Straightforward Preformulation Development.
    Wanner R; Breitsprecher D; Duhr S; Baaske P; Winter G
    J Pharm Sci; 2017 Oct; 106(10):2955-2958. PubMed ID: 28624419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevant shaking stress conditions for antibody preformulation development.
    Eppler A; Weigandt M; Hanefeld A; Bunjes H
    Eur J Pharm Biopharm; 2010 Feb; 74(2):139-47. PubMed ID: 19922795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges for the pharmaceutical technical development of protein coformulations.
    Mueller C; Altenburger U; Mohl S
    J Pharm Pharmacol; 2018 May; 70(5):666-674. PubMed ID: 28470967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
    Chadha R; Bhandari S
    J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the development of high protein concentration formulations.
    Shire SJ; Shahrokh Z; Liu J
    J Pharm Sci; 2004 Jun; 93(6):1390-402. PubMed ID: 15124199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of Neulasta (pegfilgrastim).
    Piedmonte DM; Treuheit MJ
    Adv Drug Deliv Rev; 2008 Jan; 60(1):50-8. PubMed ID: 17822802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein--solvent interactions in pharmaceutical formulations.
    Arakawa T; Kita Y; Carpenter JF
    Pharm Res; 1991 Mar; 8(3):285-91. PubMed ID: 2052513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.